Navigen, Inc.

AAA

TECHNOLOGY

Licensee of the Center For Vascular Biotherapeutics. Proof of concept in animal models of stabilizing vasculature in macular degeneration and acute lung injury based on a new signaling pathway that regulates the balance between vascular regeneration and stabilization.

CENTER NEWS
 
HIGHLIGHTS
 
SPIN OUT COMPANIES

 

BENEFITING COMPANIES

 

CENTER'S WEBSITE
 http://navigenpharma.com/
CONTACT INFORMATION
 Hunter Jackson
Chairman and CEO
(t) 801-815-5854
hunterjackson@navigenpharma.com